Literature DB >> 33127436

The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Michael G Shlipak1, Sri Lekha Tummalapalli2, L Ebony Boulware3, Morgan E Grams4, Joachim H Ix5, Vivekanand Jha6, Andre-Pascal Kengne7, Magdalena Madero8, Borislava Mihaylova9, Navdeep Tangri10, Michael Cheung11, Michel Jadoul12, Wolfgang C Winkelmayer13, Sophia Zoungas14.   

Abstract

Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems and governments should prioritize early identification and intervention for CKD. Guidelines on evaluating and managing early CKD are available but have not been universally adopted in the absence of incentives or quality measures for prioritizing CKD care. The burden of CKD falls disproportionately upon persons with lower socioeconomic status, who have a higher prevalence of CKD, limited access to treatment, and poorer outcomes. Therefore, identifying and treating CKD at the earliest stages is an equity imperative. In 2019, Kidney Disease: Improving Global Outcomes (KDIGO) held a controversies conference entitled "Early Identification and Intervention in CKD." Participants identified strategies for screening, risk stratification, and treatment for early CKD and the key health system and economic factors for implementing these processes. A consensus emerged that CKD screening coupled with risk stratification and treatment should be implemented immediately for high-risk persons and that this should ideally occur in primary or community care settings with tailoring to the local context.
Copyright © 2020 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  albuminuria; chronic kidney disease; cost-effectiveness; creatinine; cystatin; detection; glomerular filtration rate; health systems; interventions; kidney failure; proteinuria; risk models; risk stratification; screening

Year:  2020        PMID: 33127436     DOI: 10.1016/j.kint.2020.10.012

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  37 in total

1.  The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.

Authors:  Simke W Waijer; Ron T Gansevoort; George L Bakris; Ricardo Correa-Rotter; Fan-Fan Hou; Donald E Kohan; Dalane W Kitzman; Hirofumi Makino; John J V McMurray; Vlado Perkovic; Sheldon Tobe; Hans-Henrik Parving; Dick de Zeeuw; Hiddo J L Heerspink
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-01       Impact factor: 8.237

2.  Results From the WAGR Syndrome Patient Registry: Characterization of WAGR Spectrum and Recommendations for Care Management.

Authors:  Kelly A Duffy; Kelly L Trout; Jennifer M Gunckle; Shari McCullen Krantz; John Morris; Jennifer M Kalish
Journal:  Front Pediatr       Date:  2021-12-14       Impact factor: 3.418

3.  A Step Toward Health Equity for Veterans: Evidence Supports Removing Race From Kidney Function Calculations.

Authors:  Cheryl K Conner; Bijal Jain; Ambareen Khan; Marci L Laragh; Sheryl Lowery; Natasha Nichols; Janine Steffan; Jane K Weber; Samantha White
Journal:  Fed Pract       Date:  2021-08

Review 4.  Machine learning for risk stratification in kidney disease.

Authors:  Faris F Gulamali; Ashwin S Sawant; Girish N Nadkarni
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-08-10       Impact factor: 3.416

5.  Sex Disparities in the Quality of Care for CKD.

Authors:  Allison C Reaves; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2022-09-12       Impact factor: 14.978

6.  Association of Estimated GFR Calculated Using Race-Free Equations With Kidney Failure and Mortality by Black vs Non-Black Race.

Authors:  Orlando M Gutiérrez; Yingying Sang; Morgan E Grams; Shoshana H Ballew; Aditya Surapaneni; Kunihiro Matsushita; Alan S Go; Michael G Shlipak; Lesley A Inker; Nwamaka D Eneanya; Deidra C Crews; Neil R Powe; Andrew S Levey; Josef Coresh
Journal:  JAMA       Date:  2022-06-21       Impact factor: 157.335

7.  "The Disease Awareness Innovation Network" for chronic kidney disease identification in general practice.

Authors:  Francesco Pesce; Domenico Pasculli; Giuseppe Pasculli; Luca De Nicola; Mario Cozzolino; Antonio Granata; Loreto Gesualdo
Journal:  J Nephrol       Date:  2022-06-14       Impact factor: 4.393

8.  Advancing Patient-Centered Research: Enabling the Patient Voice to Be Heard.

Authors:  Kevin John Fowler
Journal:  Clin J Am Soc Nephrol       Date:  2022-02       Impact factor: 10.614

9.  Can Understanding Outcomes for Medicare Advantage Enrollees Reduce Racial and Ethnic Disparities in Kidney Disease?

Authors:  Keith C Norris
Journal:  Am J Nephrol       Date:  2021-12-07       Impact factor: 3.754

10.  The role of physical activity and miRNAs in the vascular aging and cardiac health of dialysis patients.

Authors:  Miroslava Rabajdova; Ivana Spakova; Aurel Zelko; Jaroslav Rosenberger; Peter Kolarcik; Vladimira Sobolova; Daniel Pella; Maria Marekova; Andrea Madarasova Geckova
Journal:  Physiol Rep       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.